Abstract
For the control of immunity in COVID-19 survivors and vaccinated subjects, there is an urgent need for reliable and rapid serological assays. Based on samples from 63 COVID-19 survivors up to 7 months after symptom onset, and on 50 serum samples taken before the beginning of the pandemic, we compared the performances of three commercial immunoassays for the detection of SARS-CoV-2 IgA and IgG antibodies (Euroimmun SARS-COV-2 IgA/IgG, Mikrogen recom Well SARS-CoV-2 IgA/IgG, and Serion ELISA agile SARS-CoV-2 IgA/IgG) and three rapid lateral flow (immunochromatographic) tests (Abbott PanBio COVID-19 IgG/IgM, Nadal COVID-19 IgG/IgM, and Cleartest Corona 2019-nCOV IgG/IgM) with a 50% plaque-reduction neutralization test (PRNT50) representing the gold standard. Fifty-seven out of 63 PCR-confirmed COVID-19 patients (90%) showed neutralizing antibodies. The sensitivity of the seven assays ranged from 7.0% to 98.3%, and the specificity ranged from 86.0% to 100.0%. Only one commercial immunoassay showed a sensitivity and specificity of greater than 98%.
Keywords: COVID-19; ELISA; SARS-CoV-2; flow cytometry bead-based surrogate test; lateral flow assay; plaque-reduction neutralization test.
【저자키워드】 COVID-19, SARS-CoV-2, ELISA, lateral flow assay, flow cytometry bead-based surrogate test, plaque-reduction neutralization test., 【초록키워드】 pandemic, Immunity, Neutralizing antibodies, flow cytometry, ELISA, lateral flow, sensitivity, specificity, IgG antibody, Corona, Sensitivity and specificity, IgG antibodies, serological assays, IgA, neutralization test, gold, Euroimmun, immunochromatographic, 2019, PRNT50, Abbott, symptom onset, serum samples, gold standard, PanBio, plaque-reduction neutralization test, plaque, serum sample, survivor, commercial immunoassay, well, Seven, greater, subjects, representing, ranged, PCR-confirmed COVID-19 patient, 【제목키워드】 Human, Test, detection, Rapid, novel, performance, affinity, Flow, surrogate, Lateral,